NCT03799822View on ClinicalTrials.gov

Oral Anticoagulation in Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

September 15, 2020

Study Completion Date

October 1, 2020

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban 10 MG Oral Tablet

replacement of warfarin by rivaroxaban

DIETARY_SUPPLEMENT

MK-7 2000µg thrice weekly

dietary supplement of vitamin K2 MK-7 2000µg thrice weekly

DRUG

Vitamin K Antagonist - Drug

treatment with a vitamin K antagonist

Trial Locations (1)

9300

OLV Hospital, Aalst

All Listed Sponsors
lead

Onze Lieve Vrouw Hospital

OTHER

NCT03799822 - Oral Anticoagulation in Hemodialysis | Biotech Hunter | Biotech Hunter